Was bewirkt eine leitliniengerechte Versorgung von Tumorerkrankungen?
Z Gastroenterol. 2023 Dec;61(12):1591-1592. doi: 10.1055/a-2207-7644. Epub 2023 Dec 11.NO ABSTRACTPMID:38081180 | DOI:10.1055/a-2207-7644 (Source: Zeitschrift fur Gastroenterologie)
Source: Zeitschrift fur Gastroenterologie - December 11, 2023 Category: Gastroenterology Authors: Thomas Seufferlein Source Type: research
Leitlinienreport des Addendums „Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion“ zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)
Z Gastroenterol. 2023 Dec;61(12):e706-e714. doi: 10.1055/a-2181-3162. Epub 2023 Dec 11.NO ABSTRACTPMID:38081177 | DOI:10.1055/a-2181-3162 (Source: Zeitschrift fur Gastroenterologie)
Source: Zeitschrift fur Gastroenterologie - December 11, 2023 Category: Gastroenterology Authors: Nadine Fischer Pia Lorenz Lisa Sandmann Markus Cornberg Petra Lynen Jansen Source Type: research
Antiviral Therapy of Chronic Hepatitis D Virus Infection - Addendum to the S3 Guideline "Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS)
Z Gastroenterol. 2023 Dec;61(12):e715-e732. doi: 10.1055/a-2181-3345. Epub 2023 Dec 11.NO ABSTRACTPMID:38081178 | DOI:10.1055/a-2181-3345 (Source: Zeitschrift fur Gastroenterologie)
Source: Zeitschrift fur Gastroenterologie - December 11, 2023 Category: Gastroenterology Authors: Lisa Sandmann Thomas Berg Katja Deterding Nadine Fischer Holger Hinrichsen J örg Petersen Frank Tacke Markus Cornberg Collaborators Source Type: research
Addendum „Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion“ zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)
Z Gastroenterol. 2023 Dec;61(12):1635-1653. doi: 10.1055/a-2181-3046. Epub 2023 Dec 11.NO ABSTRACTPMID:38081179 | DOI:10.1055/a-2181-3046 (Source: Zeitschrift fur Gastroenterologie)
Source: Zeitschrift fur Gastroenterologie - December 11, 2023 Category: Gastroenterology Authors: Lisa Sandmann Thomas Berg Katja Deterding Nadine Fischer Holger Hinrichsen J örg Petersen Frank Tacke Markus Cornberg Collaborators Source Type: research
Was bewirkt eine leitliniengerechte Versorgung von Tumorerkrankungen?
Z Gastroenterol. 2023 Dec;61(12):1591-1592. doi: 10.1055/a-2207-7644. Epub 2023 Dec 11.NO ABSTRACTPMID:38081180 | DOI:10.1055/a-2207-7644 (Source: Zeitschrift fur Gastroenterologie)
Source: Zeitschrift fur Gastroenterologie - December 11, 2023 Category: Gastroenterology Authors: Thomas Seufferlein Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)
Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedol...
Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research
